IPP Bureau
Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies
By IPP Bureau - April 22, 2026
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Zyax Chem takes 26% stake in Gaymed Labs
By IPP Bureau - April 22, 2026
Targets high-growth eye care expansion push
Merck unveils bio-based HPLC solvents slashing CO2 emissions by up to 29%
By IPP Bureau - April 22, 2026
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Experts discuss ways to strengthen adolescent mental health through ANUMATI 2.0
By IPP Bureau - April 22, 2026
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
Blueneem Medical Devices appoints Manoj Tumkur Venkatachala as Chief Product Officer
By IPP Bureau - April 22, 2026
Manoj has over two decades of experience in healthcare operations and biomedical engineering
Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility
By IPP Bureau - April 22, 2026
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
India–UK life sciences research to advance through new cross-border innovation corridor
By IPP Bureau - April 22, 2026
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
Centre of Excellence by Terumo India, AIG Hospitals to bridge IR skill gaps and reduce procedural risks
By IPP Bureau - April 22, 2026
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
Former VP M. Venkaiah Naidu praises Wadi Surgicals infrastructure in AMTZ, Visakhapatnam
By IPP Bureau - April 22, 2026
The plant is currently scaling towards a production capacity of nearly 3 million gloves per day
Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%
By IPP Bureau - April 22, 2026
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Moderna launches late-stage trial of mRNA bird flu vaccine
By IPP Bureau - April 22, 2026
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
By IPP Bureau - April 22, 2026
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Moderna wins EU approval for first combined flu & COVID shot for adults 50+
By IPP Bureau - April 22, 2026
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Ultomiris shows strong interim results in Phase III IgA nephropathy trial
By IPP Bureau - April 22, 2026
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
BioMed X launches AI-driven bispecific antibody research team in France
By IPP Bureau - April 21, 2026
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
